Semaglutide vs Tirzepatide
in Canada.

TL;DR — the honest short answer

On average, at maximum tolerated doses, tirzepatide has produced larger weight-loss and A1C improvements than semaglutide in head-to-head and cross-trial evidence. That doesn't mean tirzepatide is the right answer for you: side-effect tolerability, cost, and — critically — Canadian coverage often make semaglutide the more practical choice, especially for type 2 diabetes patients whose plans cover Ozempic.

What each molecule actually is

Semaglutide is a GLP-1 receptor agonist. It binds to the GLP-1 receptor, mimicking the effect of your body's natural post-meal GLP-1 hormone: slower gastric emptying, increased satiety, better glucose-dependent insulin release, and reduced glucagon.

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It hits both incretin pathways. In simplified terms, this dual mechanism is why the average effect size tends to be larger.

Brand names in Canada, decoded

Efficacy — how the trials compare

The clearest head-to-head data comes from SURMOUNT-5 (Eli Lilly's trial directly comparing tirzepatide to semaglutide for weight management) and from cross-trial comparisons of the STEP program (semaglutide) and SURMOUNT program (tirzepatide).

Roughly, at max tolerated dose over roughly 68–72 weeks:

• Semaglutide 2.4 mg (Wegovy): mean weight loss around 15% of baseline body weight.
• Tirzepatide 15 mg (Zepbound): mean weight loss around 20–22% of baseline body weight.

For A1C reduction in type 2 diabetes, tirzepatide (SURPASS program) also produced larger average A1C drops than semaglutide (SUSTAIN program). "Average" is doing important work in that sentence — individual response varies widely.

Side effects and tolerability

The GI side effect profile is broadly similar between the two: nausea, constipation, diarrhea, occasional vomiting, especially during dose escalation. Some Canadian patients tolerate one better than the other for reasons that aren't fully explained by the trial data. If one causes intolerable nausea, switching to the other is a reasonable conversation with your prescriber.

Serious warnings are the same class-wide: personal or family history of medullary thyroid carcinoma or MEN2, history of pancreatitis, pregnancy, and severe gastroparesis are all reasons to not use either drug.

Canadian cost picture

Approximate cash prices at Canadian pharmacies as of early 2026 (roughly comparable across major SK/AB/MB pharmacies):

• Ozempic — $300–$400/month.
• Wegovy — $400–$550/month.
• Mounjaro — $450–$600/month.
• Zepbound — $500–$700/month.

Tirzepatide is more expensive on average. That gap matters if you're paying out of pocket.

Coverage: SK, AB, MB, and private plans

In all three Prairie provinces, provincial drug plans generally cover Ozempic and Mounjaro for type 2 diabetes with prior-authorization criteria (usually metformin already tried), and generally do not cover Wegovy or Zepbound for chronic weight management. Private benefit plans vary — some cover the weight-management brands with prior authorization, most do not.

See the provincial detail pages: Saskatchewan, Alberta, Manitoba.

Which one is right for you?

Rules of thumb — a real prescriber will refine these for your case:

• Type 2 diabetes, provincial coverage matters most: semaglutide (Ozempic) is often the practical first move because it's more widely covered and cheaper. If A1C control isn't sufficient, tirzepatide (Mounjaro) is a reasonable next step.
• Weight management, paying out of pocket, want the largest average effect: tirzepatide (Zepbound) has the larger average effect but the higher cost.
• Weight management, cost-sensitive: semaglutide (Wegovy) delivers substantial average results at a lower price than Zepbound.
• Injection-averse, type 2 diabetes, mild-to-moderate A1C: oral semaglutide (Rybelsus) is worth a conversation.

Ready to talk to a Canadian prescriber? Take the two-minute quiz or browse the provider directory.